Brazilian Journal of Pharmaceutical Sciences · 2012 · 12 citations · 39 references
Life SciencesGeneticsMolecular GeneticsExercise PhysiologyGene TherapyMedical GeneticsMuscle DevelopmentMuscle DifferentiationMuscle PathologyMuscle PhysiologyMuscular StrengthAthletic Performance EffectsGene-targeted TherapyMuscle Fiber HypertrophyMuscle Gene TherapyMuscle HypertrophyMuscle Oxidative CapacitySkeletal Muscle WastingTissue Regeneration
Since its discovery, myostatin (MSTN) has been at the forefront of muscle therapy research because intrinsic mutations or inhibition of this protein, by either pharmacological or genetic means, result in muscle hypertrophy and hyperplasia. In addition to muscle growth, MSTN inhibition potentially disturbs connective tissue, leads to strength modulation, facilitates myoblast transplantation, promotes tissue regeneration, induces adipose tissue thermogenesis and increases muscle oxidative phenotype. It is also known that current advances in gene therapy have an impact on sports because of the illicit use of such methods. However, the adverse effects of these methods, their impact on athletic performance in humans and the means of detecting gene doping are as yet unknown. The aim of the present review is to discuss biosynthesis, genetic variants, pharmacological/genetic manipulation, doping and athletic performance in relation to the MSTN pathway. As will be concluded from the manuscript, MSTN emerges as a promising molecule for combating muscle wasting diseases and for triggering wide-ranging discussion in view of its possible use in gene doping.
39
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Markus Schuelke, Kathryn R. Wagner, Leslie E. Stolz et al. · New England Journal of Medicine · 2004 · 1.4K citations · Full text
Induction of Cachexia in Mice by Systemically Administered Myostatin
Teresa A. Zimmers, Monique V. Davies, Leonidas G. Koniaris et al. · Science · 2002 · 899 citations